72MO Homologous recombination deficiency (HRD) and genomic subgroup analysis in patients (pts) with platinum-sensitive ovarian cancer (PSOC) receiving mirvetuximab soravtansine-gynx (MIRV) in the PICCOLO clinical trial | Publicación